Karen Lizbeth Reyes-Barrera

Dr. Karen Lizbeth Reyes-Barrera

Department of Immunology, UNAM, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
CZCESAR A ZAA
CESAR A ZAA
CEClara Inés Espitia
Clara Inés Espitia
Karen Lizbeth Reyes-BarreraKaren Lizbeth Reyes-Barrera
Karen Lizbeth Reyes-Barrera
ZAZhiqiang An
Zhiqiang An
Marco Velasco-VelazquezMarco Velasco-Velazquez
Marco Velasco-Velazquez
COVID-19 patients can exhibit a wide range of clinical manifestations affecting various organs and systems. Neurological symptoms have been reported in COVID-19 patients, both during the acute phase of the illness and in cases of long-term COVID. Moderate symptoms include ageusia, anosmia, altered mental status, and cognitive impairment, and in more severe cases can manifest as ischemic cerebrovascular disease and encephalitis. In this narrative review, we delve into the reported neurological symptoms associated with COVID-19, as well as the underlying mechanisms contributing to them. These mechanisms include direct damage to neurons, inflammation, oxidative stress, and protein misfolding. We further investigate the potential of small molecules from natural products to offer neuroprotection in models of neurodegenerative diseases. Through our analysis, we discovered that flavonoids, alkaloids, terpenoids, and other natural compounds exhibit neuroprotective effects by modulating signaling pathways known to be impacted by COVID-19. Some of these compounds also directly target SARS-CoV-2 viral replication. Therefore, molecules of natural origin show promise as potential agents to prevent or mitigate nervous system damage in COVID-19 patients. Further research and the evaluation of different stages of the disease are warranted to explore their potential benefits.

12 May 2021 in Frontiers in Plant Science
Verified
Journal Article
Open access
PDF file
Karen Lizbeth Reyes-BarreraKaren Lizbeth Reyes-Barrera
Karen Lizbeth Reyes-Barrera
RSRuth Elena Soria-Guerra
Ruth Elena Soria-Guerra
RLRogelio López-Martínez
Rogelio López-Martínez
LHLeonor Huerta
Leonor Huerta
NOHEMI SALINASNOHEMI SALINAS
NOHEMI SALINAS
ÁSÁngel Gabriel Alpuche Solís
Ángel Gabriel Alpuche Solís
This year, a respiratory virus caused an emergency pandemic alert in health services around the world, showing the need for biotechnological approaches to fight these diseases. The influenza virus is one of the main viral agents that generate pandemic outbreaks. Currently, the majority of co-circulating influenza A virus (IAV) strains are adamantine‐ and oseltamivir-resistant strains, and the challenge is to find new antivirals for more efficient treatments. The antiviral entry blocker (EB) peptide is a promising candidate for blocking the virus entry into cells. The aim of this research was to express the EB peptide in the microalgae Chlamydomonas reinhardtii and test its antiviral activity against IAV in vitro. The EB peptide nucleotide sequence was introduced into the nuclear genome of microalgae using Agrobacterium tumefaciens transformation. The EB peptide amount produced in transformed microalgae was 4.99 ± 0.067% of the total soluble protein. In hemagglutination inhibition assays using influenza A/H1N1 pdm and influenza A H1N1/Virginia/ATCC/2009 strains, we reported that the EB peptide extract from the microalgae showed 100-fold higher efficiency than the EB synthetic peptide. In addition, both the EB peptide extract and synthetic peptide inhibited viral replication in MDCK cells (IC50 = 20.7 nM and IC50 = 754.4 nM, respectively); however, the EB peptide extract showed a 32-fold higher antiviral effectiveness than the synthetic peptide against influenza A/H1N1 pdm. Extracts from untransformed and transformed microalgae and synthetic peptide did not show cytotoxic effect on MDCK cell monolayers. Thus, C. reinhardtii may be a fast, safe, and effective expression platform for production of peptides with significant antiviral activity and can be used as a prophylactic treatment to reduce viral propagation.

1 July 2021 in Molecular Immunology
Verified
Journal Article
Closed access
JVJuan Voutssas-Lara
Juan Voutssas-Lara
JCJacquelynne Cervantes
Jacquelynne Cervantes
MHMarisela Hernández
Marisela Hernández
RBRaúl J. Bobes
Raúl J. Bobes
ELEdmundo Lamoyi
Edmundo Lamoyi
ESEdda Sciutto
Edda Sciutto

22 January 2015
Verified
Journal Article
Closed access
LVLeón Vélez-Hernández
León Vélez-Hernández
Karen Lizbeth Reyes-BarreraKaren Lizbeth Reyes-Barrera
Karen Lizbeth Reyes-Barrera
DRDaniela Rojas-Almaráz
Daniela Rojas-Almaráz
MCMónica Alicia Calderón-Oropeza
Mónica Alicia Calderón-Oropeza
JCJulieta Karina Cruz-Vázquez
Julieta Karina Cruz-Vázquez
JAJosé Luis Arcos-García
José Luis Arcos-García

30 January 2026 in Viruses
Verified
Journal Article
Open access
PDF file
PVPatricia Volkow
Patricia Volkow
MVMarco Villanueva-Reza
Marco Villanueva-Reza
SÁSantiago Ávila-Ríos
Santiago Ávila-Ríos
EMEnrique Mendoza-Ramirez
Enrique Mendoza-Ramirez
AVAmérica Citlali Vera-Jimenez
América Citlali Vera-Jimenez
JVJoel Armando Vazquez-Perez
Joel Armando Vazquez-Perez
Immunocompromised patients, including those with advanced HIV infection, hematologic malignancies treated with anti-CD20 monoclonal antibodies, or combined immunodeficiencies, are at increased risk of persistent SARS-CoV-2 infection. While long-term viral shedding has been described in these patients, the extent and nature of intra-host viral evolution during long-term infection remain insufficiently documented. In this study, we report longitudinal genomic analyses of SARS-CoV-2 from three immunocompromised individuals with persistent COVID-19: (i) a female patient with follicular lymphoma receiving bendamustine-rituximab therapy with 9 months of persistence, (ii) a male patient with advanced HIV infection following prolonged antiretroviral therapy interruption with 10 months of persistence, and (iii) a female patient with Good’s Syndrome characterized by combined humoral and cellular immune deficiency with apparently four years of persistence. Replication-competent virus was detected over extended periods. Sequential whole-genome sequencing revealed the gradual accumulation of non-synonymous mutations across multiple viral genes, consistent with ongoing viral replication and intra-host diversification in the absence of effective immune control. Although based on a limited number of cases, these findings provide descriptive evidence that persistent SARS-CoV-2 infection in immunocompromised hosts can be associated with sustained viral evolution. This work highlights the importance of continued virological monitoring in selected patients with prolonged infection and contributes to the understanding of SARS-CoV-2 dynamics in settings of impaired immunity.

10 July 2021 in Plant Cell, Tissue and Organ Culture (PCTOC)
Verified
Journal Article
Closed access
PDF file
KSKarla Sanchez-Alvarez
Karla Sanchez-Alvarez
SRSergio Rosales-Mendoza
Sergio Rosales-Mendoza
Karen Lizbeth Reyes-BarreraKaren Lizbeth Reyes-Barrera
Karen Lizbeth Reyes-Barrera
LMLeticia Moreno-Fierros
Leticia Moreno-Fierros
RSRuth E. Soria-Guerra
Ruth E. Soria-Guerra
ÁSÁngel Gabriel Alpuche Solís
Ángel Gabriel Alpuche Solís